The role of multimodal MRI in mild cognitive impairment and Alzheimer's disease

2021 ◽  
Author(s):  
Laust Vind Knudsen ◽  
Parisa Gazerani ◽  
Tanja Maria Michel ◽  
Manouchehr Seyedi Vafaee
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Multimodal Mri

A multimodal MRI investigation of the subventricular zone in mild cognitive impairment and Alzheimer's disease patients

2010 ◽  
Vol 469 (2) ◽  
pp. 214-218 ◽  
Author(s):  
Andrea Cherubini ◽  
Ilaria Spoletini ◽  
Patrice Péran ◽  
Giacomo Luccichenti ◽  
Margherita Di Paola ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Subventricular Zone ◽  
Multimodal Mri

scholarly journals The Role of Dietary and Lifestyle Factors in Maintaining Cognitive Health

2017 ◽  
Vol 12 (4) ◽  
pp. 268-285 ◽  
Author(s):  
Nathalie E. Marchand ◽  
Majken K. Jensen
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Lower Risk ◽  
Controlled Trial ◽  
Cognitive Health ◽  
Healthy Diets ◽  
Global Population

Concern over loss of cognitive function, including descent into Alzheimer’s disease or dementia, grips a growing percentage of men and women worldwide as the global population ages. Many studies, though not all, suggest that maintaining cognitive health, as well as slowing and even preventing cognitive decline, dementia, and Alzheimer’s disease, can be achieved by consuming healthy diets over a long enough period of time. This appears to be the case even for those who initiated dietary changes later in life, as evidenced by an intervention study assessing consumption of a healthy diet among those who were >50 years of age. All such diets share the common traits of being rich in fruits, vegetables, whole grains, and fish or seafood, while also being low in red meat and sweets. A Mediterranean-style diet shares these characteristics and has been associated with an estimated 40% lower risk of cognitive impairment, including mild cognitive impairment, dementia, and Alzheimer’s disease in prospective studies, in addition to being associated with both a 65% lower risk of mild cognitive impairment and improved cognitive performance in a notable randomized controlled trial.

Potential Role of Diffusion Tensor MRI in the Differential Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease

2008 ◽  
Vol 190 (5) ◽  
pp. 1369-1374 ◽  
Author(s):  
Daniella B. Parente ◽  
Emerson L. Gasparetto ◽  
Luiz Celso Hygino da Cruz ◽  
Roberto Cortes Domingues ◽  
Ana Célia Baptista ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Differential Diagnosis ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Potential Role ◽  
Diffusion Tensor ◽  
Diffusion Tensor Mri

scholarly journals The Role of Interleukin-33 in Patients with Mild Cognitive Impairment and Alzheimer's Disease

2020 ◽  
Author(s):  
Chih-Sung Liang ◽  
Kuan-Pin Su ◽  
Chia-Lin Tsai ◽  
Jiunn-Tay Lee ◽  
Che-Sheng Chu ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Interleukin 33

scholarly journals Specific EEG Changes Associated with Atrophy of Hippocampus in Subjects with Mild Cognitive Impairment and Alzheimer's Disease

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
D. V. Moretti ◽  
A. Prestia ◽  
C. Fracassi ◽  
G. Binetti ◽  
O. Zanetti ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Hippocampal Atrophy ◽  
Power Ratio ◽  
Relative Power ◽  
Diagnostic Role ◽  
Eeg Changes

We evaluated the association between hippocampal atrophy and increase of the EEG markers alpha3/alpha2 relative power ratio in mild cognitive impairment (MCI) and Alzheimer's disease patients. Seventy-nine subjects with MCI and 11 patients with AD underwent EEG recording and MRI scan. The MCI group was subdivided in three subgroups according to growing hippocampal atrophy. The groups were characterized by alpha3/alpha2 relative power ratio. In AD patients group mapped hippocampal regions were computed and related with alpha3/alpha2 power ratio. Results show that the increase of alpha3/alpha2 power ratio is correlated with atrophy of hippocampus both in MCI and in Alzheimer's disease patients. This finding confirms the possible diagnostic role of EEG markers as diagnostic and prognostic factors in patient with prodromal and declared Alzheimer's disease.

scholarly journals New diagnostic concepts in Alzheimer's disease

2013 ◽  
Vol 19 (4) ◽  
pp. 242-249 ◽  
Author(s):  
Anna Watkin ◽  
Sudip Sikdar ◽  
Biswadeep Majumdar ◽  
Anna V. Richman
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Clinical Practice ◽  
Mild Cognitive Impairment ◽  
Diagnostic Criteria ◽  
Current Clinical Practice ◽  
Amnestic Mci ◽  
Recent Developments

SummaryThis article gives an overview of the profile of Alzheimer's disease, its pathophysiology and recent developments in technology that enable better understanding of the mechanism of disease. The diagnostic criteria and role of biomarkers proposed are explained. The new subgroups described are outlined in table form for easy reference. Subtypes of mild cognitive impairment (MCI) are reviewed and the conversion of amnestic MCI to Alzheimer's disease is considered. The implications and change to current clinical practice form the basis of the conclusion of the article.

scholarly journals The role of Interleukin-33 in patients with mild cognitive impairment and Alzheimer’s disease

2020 ◽  
Author(s):  
Chih-Sung Liang ◽  
Kuan-Pin Su ◽  
Chia-Lin Tsai ◽  
Jiunn-Tay Lee ◽  
Che-Sheng Chu ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Clinical Studies ◽  
Digit Span ◽  
Verbal Learning ◽  
Blood Levels ◽  
Positive Trend

Abstract Background: The neuroprotective role of Interleukin (IL)-33 is supported in numerous pre-clinical studies but remains mostly uninvestigated in clinical studies of Alzheimer’s disease (AD). We aimed to examine the association between human blood levels of IL-33 and cognitive preservation in amnestic mild cognitive impairment (aMCI) and AD.Methods: A total of 100 participants (26 controls, 35 aMCI patients, and 39 AD patients) were completed twice Mini Mental State Examination (MMSE) over a 1-year interval. At the second MMSE, the 100 participants examined the plasma levels of IL-33, IL-β, IL-1 receptor agonist (IL-1RA), beta amyloid (Aβ), and tau and apolipoprotein E (ApoE) genotyping, and Hopkins Verbal Learning Test, Trail Making Test, forward and backward digit span, and Clinical Dementia Rating were performed as well. Results: IL-33 expression showed a positive trend among controls (1/26 = 3.8%), aMCI (9/35 = 25.7%), and AD (17/39 = 43.6%) (trend analysis: P < 0.001). The patients expressing IL-33 preserved their cognitive function compared with IL-33 non-expressing patients (1-year ΔMMSE: 0.16 ± 1.6 vs -1.5 ± 2.6; P = 0.006). The cognitive preservation was not associated with the lower levels of Aβ, tau, and AopE ε4, while higher levels of AopE ε4 and phosphorylated tau were indeed associated with cognitive decline. The aMCI patients with AD conversion during study period had higher proportion of IL-33(-) than non-AD converters (0.9% vs 53.3%, P = 0.04).Conclusions: IL-33 or its associated signaling pathways may represent a new treatment paradigm for aMCI and AD.

Sign in / Sign up

Export Citation Format

Share Document